ArticleCardiology journal2026
Machine learning models of inflammatory markers used in the prediction of early and late atrial fibrillation recurrence in overweight and obese patients after catheter ablation.
Article in Cardiology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInflammation is associated with atrial fibrillation (AF) recurrence after catheter ablation. This study aimed to create machine learning models of inflammatory biomarkers and clinical parameters to predict early recurrence of atrial fibrillation (ERAF) and late recurrence of atrial fibrillation (LRAF) after catheter ablation.
methodsThe study included 114 patients with abnormal body weight, defined as body mass index (BMI) > 25 kg/m², and paroxysmal, persistent, or long-standing persistent AF. Blood samples were collected at baseline and 24 hours after ablation. Almost 120 clinical and laboratory parameters were selected to develop machine learning models of ERAF and LRAF. Shapley additive explanations (SHAP) were derived to explain the obtained predictions. The models were trained and tuned for hyperparameters by five-fold cross-validation and subsequently evaluated on independent test sets using stratified sampling.
resultsERAF was observed in 20.3% of patients. LRAF was diagnosed in 26.3% of patients. The ERAF model with 5 variables - monocyte count, platelet-to-lymphocyte ratio (PLR), fibrinogen, and parameters measured before ablation, such as glomerular filtration rate (GFR) and left atrial volume - performed well in the studied cohort (mean AUC, 0.70 ± 0.06). The LRAF model with parameters such as neutrophil-to-lymphocyte ratio (NLR), soluble vascular cell adhesion molecule-1 (sVCAM-1), troponin, monocyte-to-HDL-C ratio (MHR), adiponectin, and ERAF also showed valuable performance (mean AUC, 0.77 ± 0.11).
conclusionsThe machine learning model based on inflammatory biomarkers is a valuable tool for predicting ERAF. The combination of ERAF and inflammatory biomarkers significantly improves LRAF prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.